ANI Pharmaceuticals ANIP Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $29.49M+7.3% | $27.49M+3.3% | $26.62M+211% | $8.55M-45.5% | $15.68M+253% | ||
| $20.92M-7.5% | $22.61M-0.1% | $22.63M-2.8% | $23.28M+1.7% | $22.89M+1.3% | ||
| $10.19M+4.3% | $9.77M+0.8% | $9.69M+0.9% | $9.6M+8.3% | $8.87M+25.6% | ||
| $2.52M+6.7% | $2.36M-87.5% | $18.8M+632% | -$3.54M-4.5% | -$3.38M+80.7% | ||
| $358K+2.0% | $351K+3.2% | $340K-0.3% | $341K+5.2% | $324K+0.3% | ||
| -$25.53M-192% | $27.86M+3.3% | $26.97M+391% | $5.49M+408% | -$1.78M-107% | ||
| $437K— | —— | $8.16M+799% | $908K+45.3% | $625K-7.4% | ||
| $5.36M— | —— | $13.77M+348% | $3.08M-44.6% | $5.55M— | ||
| -$2.69M-160% | $4.46M-30.9% | $6.45M+166% | -$9.84M-349% | $3.95M— | ||
| $14.09M— | $0+100% | -$12.55M-15.2% | -$10.89M-246% | $7.44M— | ||
| $5.75M+2,007% | $273K-91.3% | $3.14M+846% | $332K+136% | -$921K— | ||
| $453K-18.4% | $555K+55.0% | $358K-9.1% | $394K-12.8% | $452K+15.3% | ||
| $58.38M+92.2% | $30.37M-31.1% | $44.06M-41.9% | $75.81M+117% | $34.99M+121% | ||
| $6.07M+388% | $1.24M-79.6% | $6.1M+52.0% | $4.01M+62.2% | $2.47M+3.3% | ||
| $5.25M+3,202% | $159K+165% | $60K-97.9% | $2.9M-83.3% | $17.37M+20,100% | ||
| -$11.32M-707% | -$1.4M+77.2% | -$6.16M+10.8% | -$6.91M+65.2% | -$19.85M-85.8% | ||
| $0— | $0-100% | $344K-15.5% | $407K+0.2% | $406K0.0% | ||
| $19.76M+3,133% | $611K-41.5% | $1.04M+89.5% | $551K-94.5% | $10M+3,046% | ||
| $4.06M+167% | -$6.09M-400% | $2.03M0.0% | $2.03M0.0% | $2.03M-99.3% | ||
| $2.2M+116% | -$13.57M-239% | $9.79M+688% | $1.24M-51.0% | $2.53M— | ||
| -$21.62M-366% | -$4.64M— | —— | -$1.75M+82.4% | -$9.91M— | ||
| $156K+112% | -$1.35M-335% | $576K-31.5% | $841K+383% | -$297K+24.8% | ||
| $25.59M+11.4% | $22.98M-48.7% | $44.81M-34.1% | $68M+1,276% | $4.94M+4,118% | ||
| $7.82M+69.7% | $4.61M-45.5% | $8.46M+70.3% | $4.97M-44.2% | $8.9M+72.8% | ||
| -$6.07M-672% | $1.06M+658% | $140K-99.1% | $16.19M+5,580% | $285K-84.6% | ||
| $358K+2.0% | $351K+3.2% | $340K-0.3% | $341K+5.2% | $324K+0.3% | ||
| -$182K+96.8% | -$5.73M+60.4% | -$14.47M— | $0+100% | -$12.09M-539% | ||
| -$4.74M-177% | $6.12M+47.0% | $4.17M-59.2% | $10.22M+160% | $3.93M-48.5% | ||
| -$2.69M-160% | $4.46M-30.9% | $6.45M+166% | -$9.84M-349% | $3.95M— | ||
| -$6.45M— | $0-100% | $1.32M-78.7% | $6.22M+95.0% | $3.19M-33.6% | ||
| -$14.66M— | —— | $15.22M+23.5% | $12.32M+1,033% | $1.09M— | ||
| -$21M-473% | $5.62M— | —— | —— | -$17.08M-414% | ||
| $453K-18.4% | $555K+55.0% | $358K-9.1% | $394K-12.8% | $452K+15.3% | ||
| $20.92M-7.5% | $22.61M-0.1% | $22.63M-2.8% | $23.28M+1.7% | $22.89M+1.3% | ||
| $5.25M+3,202% | $159K+165% | $60K-97.9% | $2.9M-83.3% | $17.37M+20,100% | ||
| $784K+3,633% | $21K-97.2% | $741K— | —— | $1.02M— | ||
| $1.09M— | —— | —— | —— | $0— | ||
| -$6.07M— | —— | —— | —— | $285K— | ||
| $52.3M+79.6% | $29.12M-23.3% | $37.95M-47.1% | $71.8M+121% | $32.52M+141% | ||
| $52.3M+79.6% | $29.12M-23.3% | $37.95M-47.1% | $71.8M+121% | $32.52M+141% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ANI Pharmaceuticals generate?
- ANI Pharmaceuticals (ANIP) generated $208.6M in operating cash flow over the trailing twelve months.
- What is ANI Pharmaceuticals's free cash flow?
- After $17.4M of capital expenditures, ANI Pharmaceuticals's free cash flow was $191.2M over the trailing twelve months, up 187.0% year over year.
- Where does ANI Pharmaceuticals's cash flow data come from?
- Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
